Back to search results

Observational Study of Antibiotic Duration for Necrotizing Soft Tissue Infections

This study is looking at whether a shorter course of antibiotics is as safe and effective as a longer course for people with Necrotizing Soft Tissue Infection (NSTI), a serious skin and soft tissue infection. You could be eligible if you are an adult (18 years or older) with NSTI who is being seen in the Emergency Department and by the Emergency General Surgery service. The study will compare a 48-hour course of antibiotics (Clindamycin, Vancomycin, Piperacillin Tazobactam) to a 7-day course. Researchers want to see if the shorter course leads to similar rates of complications and death. The study is currently unclear on its recruitment status and plans to enroll 50 participants.

Study design
This is an observational study, meaning researchers will watch and collect information about participants. It is not specified if participants are randomly assigned to a treatment group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety and mortality rate will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06002607

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

Recruiting
Not specifiedAges 18+Observational
University of California, Irvine
~50 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Antibiotic duration (short course)Antibiotic duration (extended course)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of the antibiotic course duration
Measured over Through study completion, an average of 1 year
+1 more outcome measured

Conditions

Necrotizing Soft Tissue Infection

Explore related trials

Necrotizing soft tissue infection

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Areg Grigorian, MD · PRINCIPAL_INVESTIGATOR · University of California, Irvine

Who to contact

Areg Grigorian, MD
[email protected]
8184389093
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients 18 years of age or older with all following criteria:
Presenting to the Emergency Department with history, exam and/or imaging concerning NSTI, AND
Patients who undergo consultation by the Emergency General Surgery service, AND
Patients included must have skin or soft tissue findings consistent with NSTI (erythema, crepitus, or pain out of proportion to exam), AND
Systemic signs of infection including fever (temperature \>38.0°C) or leukocytosis (≥11,000 peripheral white cells per cubic millimeter), AND
Patients who undergo excisional debridement and/or amputation to achieve source control.

Exclusion

Pregnant patients
Prisoners
Patients with bacteremia upon admission
Patients unable to provide consent (including no legally authorized representative)

What this trial measures

  • Safety of the antibiotic course durationThrough study completion, an average of 1 year

    In-hospital complications

  • Mortality rateThrough study completion, an average of 1 year

    In-hospital mortality